OPHL.F Stock Overview
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Ono Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥15.96 |
| 52 Week High | JP¥20.63 |
| 52 Week Low | JP¥15.96 |
| Beta | 0.18 |
| 1 Month Change | -4.09% |
| 3 Month Change | n/a |
| 1 Year Change | -20.81% |
| 3 Year Change | -36.29% |
| 5 Year Change | n/a |
| Change since IPO | -50.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| OPHL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -3.2% |
| 1Y | -20.8% | 9.7% | 19.3% |
Return vs Industry: OPHL.F underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: OPHL.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| OPHL.F volatility | |
|---|---|
| OPHL.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OPHL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OPHL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1717 | 3,761 | Gyo Sagara | www.ono-pharma.com |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Ono Pharmaceutical Co., Ltd. Fundamentals Summary
| OPHL.F fundamental statistics | |
|---|---|
| Market cap | US$6.80b |
| Earnings (TTM) | US$825.40m |
| Revenue (TTM) | US$3.22b |
8.2x
P/E Ratio2.1x
P/S RatioIs OPHL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPHL.F income statement (TTM) | |
|---|---|
| Revenue | JP¥498.07b |
| Cost of Revenue | JP¥121.74b |
| Gross Profit | JP¥376.33b |
| Other Expenses | JP¥248.72b |
| Earnings | JP¥127.61b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 271.68 |
| Gross Margin | 75.56% |
| Net Profit Margin | 25.62% |
| Debt/Equity Ratio | 0% |
How did OPHL.F perform over the long term?
See historical performance and comparison